Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1365-2559.2011.03868.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pilot training for clinical research professionals in using empathy to recognize and respond to implicit bias in research recruitment and retention.
J Clin Transl Sci
November 2024
NYU Clinical and Translation Science Institute, NYU Langone Health and NYU Grossman School of Medicine, New York, NY, USA.
Recruiting and retaining research participants is challenging because it often requires overcoming structural barriers and addressing how histories of mistrust and individuals' lived experiences affect their research engagement. We describe a pilot workshop designed to educate clinical research professionals on using empathy skills to recognize and mitigate bias to improve recruitment and retention. In a post-workshop survey (22/31 participants completed), 94% agreed the workshop helped them practice perspective-taking, recognize implicit bias, and identify opportunities for empathy.
View Article and Find Full Text PDFSarcolemma resilience and skeletal muscle health require O-mannosylation of dystroglycan.
Skelet Muscle
January 2025
Department of Molecular Physiology and Biophysics, and Department of Neurology, Howard Hughes Medical Institute, Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Center, Roy J. and Lucille A. Carver College of Medicine, The University of Iowa, Iowa City, Iowa, USA.
Background: Maintaining the connection between skeletal muscle fibers and the surrounding basement membrane is essential for muscle function. Dystroglycan (DG) serves as a basement membrane extracellular matrix (ECM) receptor in many cells, and is also expressed in the outward-facing membrane, or sarcolemma, of skeletal muscle fibers. DG is a transmembrane protein comprised of two subunits: alpha-DG (α-DG), which resides in the peripheral membrane, and beta-DG (β-DG), which spans the membrane to intracellular regions.
View Article and Find Full Text PDFModular comparison of untargeted metabolomics processing steps.
Anal Chim Acta
January 2025
Christian Doppler Laboratory for Innovative Gut Health Concepts of Livestock, Austria; BOKU University, Vienna, Dept. IFA-Tulln, Institute of Bioanalytics and Agro-Metabolomics, Tulln, Austria.
Background: Untargeted metabolomics requires robust and reliable strategies for data processing to extract relevant information form the underlying raw data. Multiple platforms for data processing are available, but the choice of software tool can have an impact on the analysis. This study provides a comprehensive evaluation of four workflows based on commonly used metabolomics software tools: XCMS, Compound Discoverer, MS-DIAL, and MZmine.
View Article and Find Full Text PDFFeasibility, acceptability, and preliminary impact of "Supper Heroes", a family-based sustainable diet intervention.
Appetite
January 2025
Department of Family Relations and Applied Nutrition, University of Guelph, Guelph, Canada. Electronic address:
The primary objective of this research was to evaluate the feasibility and acceptability of "Supper Heroes", a superhero-themed mobile health (mHealth) intervention designed to reduce food waste and increase plant-based protein food intake among families with children aged 9-14 in Ontario, Canada. A single arm, pre-post mixed methods design was used to evaluate the intervention. The 4-month mHealth intervention included 7 online modules with infographics, videos, and activities to help families reduce their food waste and eat more plant-based protein foods.
View Article and Find Full Text PDFDrug Development.
Alzheimers Dement
December 2024
Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, CA, USA.
Background: Participant dropout from study treatment in a clinical trial can leave a trial underpowered, produce bias in statistical analysis, and limit interpretability of study results. Retaining participants in clinical trials for the full study duration is therefore as important as participant recruitment. This analysis aims to identify the baseline characteristics of participants who discontinued during the blinded phase of one of the first and largest preclinical AD trial completed to date, the Anti-Amyloid treatment in Asymptomatic AD (A4) Study.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!